Effect of Motivational Therapy on Schizophrenia With Cannabis Misuse (SCHIZOCAN)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00798109 |
Recruitment Status
:
Completed
First Posted
: November 25, 2008
Last Update Posted
: June 16, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Schizophrenia Cannabis Dependence, Continuous | Behavioral: Motivational therapy Behavioral: Usual care | Not Applicable |
Schizophrenia is a severe mental illness with a lifetime morbidity risk close to 1 %, involving both genetic and environmental risk factors. Prospective studies have shown that heavy use of cannabis in adolescence moderately increases the risk of developing schizophrenia. Many data have also suggested that the co-occurrence of cannabis abuse in patients with schizophrenia has a deleterious impact on the clinical outcome of schizophrenia. Cannabis abuse by schizophrenic patients is a significant public health problem for which there is no empirically validated treatment. We are presently studying the efficiency of motivational therapy on cannabis consumption in patients with schizophrenia.
330 patients with schizophrenia and cannabis abuse or dependence (according to DSM-IV criteria) are randomly assigned to 4 motivational interview during one month or usual intensive treatment. Treatment is conducted in outpatient which are evaluated at the inclusion and at 6 month with Time-Line Follow Bach for the consumption, PANSS score, number of relapse…). A outcome measure was urinalysis results providing an objective measure of cannabis use throughout the six month of the trial.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 97 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open Multicentric Randomized Clinical Trial Assessing the Impact of Motivational Interviewing on Cannabis Consumption in Patients With Psychiatric Disease |
Study Start Date : | November 2008 |
Actual Primary Completion Date : | October 2012 |
Actual Study Completion Date : | April 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: Motivational Therapy
Four motivational interview for cannabis abuse in schizophrenia population during one month
|
Behavioral: Motivational therapy
One hour of motivational therapy each weak during 4 weeks
|
Usual Care
Usual care with intensive psychotherapy
|
Behavioral: Usual care
Patients received at least six hour of usual therapy, as in the experimental group
|
- Cannabis consumption evaluated by the Time-Line Follow Back at 6 months with mean percentage of abstinent day [ Time Frame: inclusion, 3 month, 6 month, 12 month ]
- PANSS, GAF, number of DSM-IV criteria of cannabis dependence, May scale for treatment response, SF-12, la URICA, number of hospitalisation, mean number of joints per week, D9THC urinanalysis at 6M and cannabis consumption evaluated by the TLFB at 6M [ Time Frame: inclusion, 3 month, 6 month, 12 month. Only inclusion and 6 month for urianalysis ]PANSS : global, positive, negative, general scores

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
INCLUSION CRITERIA:
- Schizophrenia or schizo-affective disorder according to DSM-IV criteria
- Meeting DSM-IV criteria for actual cannabis abuse or dependance
- in current and regular contact with mental health service
- with an age at interview of 18 years or more
- No evidence of organic brain disease or clinically significant concurrent medical illness or learning disability
- Written informed consent was obtained from all subjects (patients and parents).
EXCLUSION CRITERIA:
- Not membership to a regime of social security or to a CMU

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00798109
France | |
Service de psychiatrie (Pr Adès) | |
Colombes, France, 92700 |
Principal Investigator: | Caroline DUBERTRET, MD,PhD | Assistance Publique - Hôpitaux de Paris |
Responsible Party: | Assistance Publique - Hôpitaux de Paris |
ClinicalTrials.gov Identifier: | NCT00798109 History of Changes |
Other Study ID Numbers: |
P 070156 AOM 07007 ( Other Identifier: French Ministry ) |
First Posted: | November 25, 2008 Key Record Dates |
Last Update Posted: | June 16, 2014 |
Last Verified: | June 2014 |
Keywords provided by Assistance Publique - Hôpitaux de Paris:
Schizophrenia Cannabis misuse comorbidity Motivational interview Randomised open trial |
Additional relevant MeSH terms:
Schizophrenia Marijuana Abuse Substance-Related Disorders |
Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders Chemically-Induced Disorders |